Annual report pursuant to Section 13 and 15(d)

4. BUSINESS ACQUISITION

v3.5.0.2
4. BUSINESS ACQUISITION
12 Months Ended
Apr. 30, 2016
Equity Method Investments and Joint Ventures [Abstract]  
BUSINESS ACQUISITION

In June 2013, the Company completed the purchase of Bio Blue Bird.  Shares for both Austrianova and the Company originally held in escrow under the SG Austria APA were returned to the original owners. The 100,000,000 shares of the Company were cancelled. The acquisition was accounted for under ASC Topic 805, “Business Combination.” Accordingly, the assets and liabilities were fair valued and purchase accounting applied.

 

The assets of Bio Blue Bird are licenses related to the Cell-in-a-Box® technology with a fair value of $1,549,427. The assets acquired were accounted for at the fair value at the acquisition date based on current information that management believes is reasonable. After the acquisition, Bio Blue Bird became a wholly-owned subsidiary of the Company.

 

Since the Company’s acquisition of Bio Blue Bird, no revenues have been generated from the licenses; therefore, no pro-forma information has been prepared. The licenses will be used in the development of the Company’s product candidate in advanced pancreatic cancer.